Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
2a9UKvSuWUDaYUgs
